Literature DB >> 11090715

Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.

C Canthaboo1, L Williams, D K Xing, M J Corbel.   

Abstract

New generation acellular pertussis vaccines were compared with the established whole cell pertussis vaccine for the induction of humoral and cellular immune-responses in mice. At the same time, the in vivo protective effect of these two types of vaccine was also compared in both intracerebral (ic) and aerosol challenge models. In general, whole cell vaccine induced lower antibody titres to pertussis toxin, filamentous haemagglutinin and pertactin than the acellular vaccine. Nitric oxide concentration in macrophage cultures was used as a marker for macrophage activation. The nitric oxide concentrations in the macrophage cultures from mice following immunisation with the whole cell vaccine were higher than those from mice immunised with the acellular vaccine, which indicated that the whole cell vaccine was more effective than the acellular vaccine in activating macrophages. This was associated with better protection in vivo after challenge. After ic challenge of mice following immunisation with whole cell or acellular vaccine, 90% of the whole cell vaccine group survived compared with 40% of the acellular vaccine group at the vaccine dose selected. Following aerosol challenge, mice in the whole cell vaccine group showed faster clearance of bacteria from the lungs than those in the acellular vaccine group. Our findings suggest that the different types of pertussis vaccines may achieve protection in different ways and that CMI may play an important role in eliminating bacteria which escape humoral defence mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090715     DOI: 10.1016/s0264-410x(00)00253-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Characterization of co-purified acellular pertussis vaccines.

Authors:  Yinghua Xu; Yajun Tan; Catpagavalli Asokanathan; Shumin Zhang; Dorothy Xing; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Relationship of immunogenicity to protective potency in acellular pertussis vaccines.

Authors:  Dorothy Xing; Catpagavalli Asokanathan; Ying Hua Xu; Barbara Bolgiano; Alex Douglas-Bardsley; Shumin Zhang; Junzhi Wang; Michael Corbel
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Seroprevalence of pertussis in China: need to improve vaccination strategies.

Authors:  Yinghua Xu; Lichan Wang; Jin Xu; Xinjian Wang; Chen Wei; Peng Luo; Xiao Ma; Qiming Hou; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

5.  Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.

Authors:  Pablo D Becker; Gustavo M Bertot; David Souss; Thomas Ebensen; Carlos A Guzmán; Saúl Grinstein
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

6.  T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.

Authors:  C M Ausiello; R Lande; P Stefanelli; C Fazio; G Fedele; R Palazzo; F Urbani; P Mastrantonio
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

7.  Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection.

Authors:  René H M Raeven; Jolanda Brummelman; Jeroen L A Pennings; Olaf E M Nijst; Betsy Kuipers; Laura E R Blok; Kina Helm; Elly van Riet; Wim Jiskoot; Cecile A C M van Els; Wanda G H Han; Gideon F A Kersten; Bernard Metz
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

8.  Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.

Authors:  Seung Beom Han; Kyu Ri Kang; Dong Ho Huh; Hee Chul Lee; Soo Young Lee; Jong-Hyun Kim; Jae Kyun Hur; Jin Han Kang
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

9.  Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model.

Authors:  Marta Prygiel; Ewa Mosiej; Karol Wdowiak; Paulina Górska; Maciej Polak; Klaudia Lis; Katarzyna Krysztopa-Grzybowska; Aleksandra Anna Zasada
Journal:  Med Microbiol Immunol       Date:  2021-08-02       Impact factor: 3.402

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.